TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.

Ian E Krop et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.